Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (Nasdaq: NKTR) generates a steady flow of news tied to its role as a clinical-stage biotechnology company focused on autoimmune and chronic inflammatory diseases. Company announcements emphasize progress with its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), a regulatory T cell stimulator and IL-2 pathway agonist being evaluated in multiple mid-stage trials.
News coverage frequently highlights clinical data from the REZOLVE-AD Phase 2b study in moderate-to-severe atopic dermatitis and the REZOLVE-AA Phase 2b study in severe-to-very-severe alopecia areata. Press releases describe topline results, detailed efficacy and safety outcomes, and analyses in subgroups such as patients with atopic dermatitis and a history of asthma, including Asthma Control Questionnaire (ACQ-5) findings.
Investors and observers can also find updates on regulatory interactions, such as the U.S. Food and Drug Administration granting Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata. Additional news items cover Nektar’s participation in scientific and investor conferences, late-breaking oral presentations at major dermatology and allergy meetings, and corporate events like equity offerings and compliance updates related to its Nasdaq Capital Market listing.
This news page aggregates these disclosures so readers can follow developments in Nektar’s immunology pipeline, including rezpegaldesleukin and other programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. For those tracking NKTR stock or the evolution of Treg-focused therapies, this feed provides a centralized view of clinical milestones, financial communications and key corporate announcements.
Nektar (Nasdaq: NKTR) will host an investor conference call and live webcast to review topline 36-week induction results from the ongoing Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin for severe-to-very-severe alopecia areata.
The event is scheduled for December 16, 2025 at 8:00 AM ET / 5:00 AM PT. Results will be released in a morning press release and presented on the webcast; slides and the press release will be posted in the company's events section at https://ir.nektar.com/events-and-presentations/events. A replay will be available for at least 30 days after the event.
Nektar Therapeutics (NASDAQ:NKTR) announced inducement grants under Nasdaq Listing Rule 5635(c)(4) for two newly hired employees totaling 18,310 non-qualified stock options under Nektar's 2025 Inducement Plan.
Grant details: 7,260 options granted on Nov 25, 2025 at an exercise price of $60.35 (closing price that day), and 11,050 options granted on Dec 4, 2025 at an exercise price of $57.69 (closing price that day). Options have an 8-year term and vest over 4 years with 1/4 vesting after one year and the remainder vesting monthly over the next three years, subject to continued employment and plan/option agreement terms.
Nektar Therapeutics (Nasdaq: NKTR) presented new REZOLVE-AD Phase 2b data at ACAAI on Nov 8, 2025 showing statistically significant, clinically meaningful improvements in asthma control and atopic dermatitis endpoints with rezpegaldesleukin.
In 99 patients with AD and asthma, mean ACQ-5 scores improved at Week 16 versus placebo (two dose arms p<0.05); placebo worsened. In patients with baseline ACQ-5 ≥0.5 (N=53) placebo-adjusted ACQ-5 reductions ranged 0.7–1.0; in uncontrolled asthma (N=25) reductions ranged 1.0–1.4. Rezpegaldesleukin 24 μg/kg q2w met primary and key secondary AD endpoints (EASI, EASI-75, EASI-90, vIGA-AD, itch) at Week 16 and supports a 24-week induction for Phase 3.
Nektar Therapeutics (Nasdaq: NKTR) reported third-quarter 2025 results for the period ended September 30, 2025. Cash and marketable securities were $270.2M (includes July secondary offering net proceeds and ATM proceeds); company expects cash to support operations into Q2 2027. Revenue was $11.8M in Q3 2025 versus $24.1M in Q3 2024, reflecting the December 2024 sale of the Huntsville manufacturing facility. R&D expense was $27.3M in Q3; Net loss was $35.5M ($1.87 per share) in Q3 and $128.0M year-to-date.
Key clinical and corporate items: REZOLVE-AD data presented at EADV and ACAAI; FDA granted Fast Track for rezpegaldesleukin in severe-to-very-severe alopecia areata; company raised capital including a $115M gross public offering and ATM proceeds.
Nektar Therapeutics (Nasdaq: NKTR) announced that company management will present at the Jefferies Global Healthcare Conference in London, held November 17-20, 2025.
The company will host a fireside chat on Thursday, November 20, 2025, webcast live at 11:00 a.m. GMT / 3:00 a.m. PT. The webcast is accessible via the company’s Investor Events webpage and a replay will be available for 30 days. Investors seeking one-on-one meetings should contact their Jefferies representative.
Nektar (Nasdaq:NKTR) will announce its third-quarter 2025 financial results on Thursday, November 6, 2025 after the U.S. market close. Howard Robin, President and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT to review results. A press release and an audio-only webcast link will be posted on the company's investor relations site at https://ir.nektar.com/. The web broadcast replay will be available through December 6, 2025. Investors must pre-register to receive dial-in details and a PIN to access the live call.
Nektar Therapeutics (Nasdaq:NKTR) announced that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and Treg proliferator, was accepted for a late-breaking oral abstract presentation at the ACAAI 2025 Annual Scientific Meeting.
The oral presentation (Abstract ID: 7005) titled "Rezpegaldesleukin Novel Treg-Inducing Therapy Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial" will be delivered by Jonathan Corren, MD on Saturday, November 8, 2025 at 5:33 PM ET in Room W231. The meeting runs November 6–10, 2025 in Orlando, and the presentation will be posted on Nektar's Scientific Publications page after the formal presentation.
Nektar Therapeutics (Nasdaq: NKTR) announced positive results from its REZOLVE-AD Phase 2b study of rezpegaldesleukin for moderate-to-severe atopic dermatitis at the EADV Congress. The study met its primary endpoint with significant mean improvement in EASI scores at week 16 across all treatment arms versus placebo.
The high dose (24 µg/kg q2w) demonstrated strong efficacy with 61% mean EASI improvement, 42% EASI-75 response, and 20% vIGA-AD 0/1 response. Notably, patients who crossed over from placebo showed deepening responses after 24 weeks, with EASI-75 reaching 62% and vIGA-AD 0/1 reaching 38%.
The drug showed a favorable safety profile with 60.3% treatment-emergent adverse events across treatment arms, comparable to placebo's 57.5%, and only 1.6% serious adverse events.
Nektar Therapeutics (NASDAQ:NKTR) has announced that results from its REZOLVE-AD Phase 2b study for rezpegaldesleukin in atopic dermatitis will be presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris.
The presentation will cover primary and secondary endpoints from the 16-week induction phase, including multiple patient-reported outcomes. Additionally, new data will be presented from placebo patients who crossed over to high-dose rezpegaldesleukin treatment. Dr. Jonathan Silverberg will deliver the late-breaker oral presentation on September 18th at 14:45.
Nektar Therapeutics (NASDAQ:NKTR) announced its participation in two upcoming investor conferences in September 2025. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 10:30 AM ET in New York City, and the Stifel Virtual Immunology and Inflammation Forum on September 15 at 2:30 PM ET.
Both presentations will be available via webcast through the company's investor relations website, with replays accessible for 30 days. Investors interested in one-on-one meetings with management can arrange them through their representatives.